TUDCA slows retinal degeneration in two different mouse models of retinitis pigmentosa and prevents obesity in Bardet-Biedl syndrome type 1 mice

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 1, 2012, Pages 100-106

  Drack, Arlene V ^a   Dumitrescu, Alina V ^a   Bhattarai, Sajag ^a   Gratie, Daniel ^a   Stone, Edwin M ^a,b   Mullins, Robert ^a   Sheffield, Val C ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAUROURSODEOXYCHOLIC ACID; BBS1 PROTEIN, MOUSE; CHOLAGOGUE; MICROTUBULE ASSOCIATED PROTEIN; TAUROCHENODEOXYCHOLIC ACID;

A WAVE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B WAVE; BARDET BIEDL SYNDROME; BODY WEIGHT; CELL STRUCTURE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; HISTOLOGY; MOUSE; NONHUMAN; OBESITY; OPTICAL COHERENCE TOMOGRAPHY; PHOTORECEPTOR OUTER SEGMENT; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA THICKNESS; RETINITIS PIGMENTOSA; VISUAL SYSTEM PARAMETERS; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; GENETICS; PATHOPHYSIOLOGY; RETINA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BARDET-BIEDL SYNDROME; CHOLAGOGUES AND CHOLERETICS; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; INJECTIONS, SUBCUTANEOUS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; OBESITY; RETINA; RETINAL DEGENERATION; RETINITIS PIGMENTOSA; TAUROCHENODEOXYCHOLIC ACID; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84857946871     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8544     Document Type: Article

References (39)

1. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358:2240-2248.
2. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358:2231-2239.
3. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19:979-990.
4. Boatright JH, Moring AG, McElroy C, et al. Tool from ancient pharmacopoeia prevents vision loss. Mol Vis. 2006;12:1706-1714.
5. Boatright JH, Nickerson JM, Moring AG, Pardue MT. Bile acids in treatment of ocular disease. J Ocul Biol Dis Infor. 2009;2:149-159.
6. Phillips MJ, Walker TA, Choi HY, et al. Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30. Invest Ophthalmol Vis Sci. 2008; 49:2148-2155.
7. Ramalho RM, Viana RJ, Low WC, Steer CJ, Rodrigues CM. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol Med. 2008;14:54-62.
8. Ramalho RM, Borralho PM, Castro RE, Sola S, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J Neurochem. 2006;98:1610-1618.
9. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002;99:10671-10676.
10. Keene CD, Rodrigues CM, Eich T, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001;171:351-360.
11. Fernandez-Sanchez L, Lax P, Pinilla I, Martin-Nieto J, Cuenca N. Tauroursodeoxycholic acid prevents retinal degeneration in transgenic P23H rats. Invest Ophthalmol Vis Sci. 2011;52:4998-5008.
12. Davis RE, Swiderski RE, Rahmouni K, et al. A knockin mouse model of the Bardet-Biedl syndrome 1 M390R mutation has cilia defects, ventriculomegaly, retinopathy, and obesity. Proc Natl Acad Sci USA. 2007;104:19422-19427.
13. Bardet G. On congenital obesity syndrome with polydactyly and retinitis-pigmentosa (a contribution to the study of clinical forms of hypophyseal obesity). (Reprinted from a Thesis, Faculte De Medecine De Paris. 1920). Obes Res. 1995;3:387-399.
14. Biedl A. A pair of siblings with adiposo-genital dystrophy (reprinted 1922). Obes Res. 1995;3:404-404.
15. Nachury MV, Loktev AV, Zhang Q, et al. A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. Cell. 2007;129:1201-1213.
16. Loktev AV, Zhang Q, Beck JS, et al. A BBSome subunit links ciliogenesis, microtubule stability, and acetylation. Dev Cell. 2008; 15:854-865.
17. Seo S, Baye LM, Schulz NP, et al. BBS6, BBS10, and BBS12 form a complex with CCT/TRiC family chaperonins and mediate BBSome assembly. Proc Natl Acad Sci U S A. 2010;107:1488-1493.
18. Sheffield VC. The blind leading the obese: the molecular pathophysiology of a human obesity syndrome. Trans Am Clin Climatol Assoc. 121:172-181; discussion 181.
19. Seo S, Guo DF, Bugge K, Morgan DA, Rahmouni K, Sheffield VC. Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling. Hum Mol Genet. 2009;18:1323-1331.
20. Chang B, Hawes NL, Pardue MT, et al. Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene. Vision Res. 2007;47:624-633.
21. Chang B, Khanna H, Hawes N, et al. In-frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse. Hum Mol Genet. 2006;15:1847-1857.
22. Johnson LV, Blanks JC. Application of acrylamide as an embedding medium in studies of lectin and antibody binding in the vertebrate retina. Curr Eye Res. 1984;3:969-974.
23. Sola S, Castro RE, Laires PA, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med. 2003;9:226-234.
24. Ramalho RM, Ribeiro PS, Sola S, Castro RE, Steer CJ, Rodrigues CM. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem. 2004;90:567-575.
25. Ozcan L, Ergin AS, Lu A, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9:35-51.
26. Sola S, Aranha MM, Steer CJ, Rodrigues CM. Game and players: mitochondrial apoptosis and the therapeutic potential of ursodeoxycholic acid. Curr Issues Mol Biol. 2007;9:123-138.
27. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137-1140.
28. Beuers U, Kullak-Ublick GA, Pusl T, Rauws ER, Rust C. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? Clin Rev Allergy Immunol. 2009;36:52-61.
29. Sola S, Ma X, Castro RE, Kren BT, Steer CJ, Rodrigues CM. Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor beta1-induced apoptosis of rat hepatocytes. J Biol Chem. 2003; 278:48831-48838.
30. Song S, Liang JJ, Mulhern ML, Madson CJ, Shinohara T. Cholesterolderived bile acids enhance the chaperone activity of α-crystallins. Cell Stress Chaperones. 2011;16:475-480.
31. Rodrigues CM, Spellman SR, Sola S, et al. Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab. 2002;22:463-471.
32. Heubi JE, Wiechmann DA, Creutzinger V, et al. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition- associated liver disease. J Pediatr. 2002;141:237-242.
33. Uy MC, Talingdan-Te MC, Espinosa WZ, Daez ML, Ong JP. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: a meta-analysis. Obes Surg. 2008;18:1532-1538.
34. Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr. 2000;136:739-743.
35. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 201059:1899-1905.
36. Bellentani S, Chao YC, Ferretti I, Panini R, Tiribelli C. Chronic administration of ursodeoxycholic and tauroursodeoxycholic acid changes microsomal membrane lipid content and fatty acid compositions in rats. Biochem Biophys Res Commun. 1996;220:479-483.
37. Song P, Zhang Y, Klaassen CD. Dose-response of five bile acids on serum and liver bile acid concentrations and hepatotoxicity in mice. Toxicol Sci. 2011;123:359-367.
38. Jammoul F, Wang Q, Nabbout R, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol. 2009;65: 98-107.
39. Leon A, Levick WR, Sarossy MG. Lesion topography and new histological features in feline taurine deficiency retinopathy. Exp Eye Res. 1995;61:731-741.